CAMERA: Combination antibiotic treatment for Methicillin Resistant Staphylococcus Aureus Bacteraemia - a Randomised Controlled Trial [ 2015 - 2019 ]

Research Grant

Researchers: A/Pr Joshua Davis (Principal investigator) ,  A/Pr Mark Chatfield ,  A/Pr Steven Tong ,  Dr Matthew O'Sullivan ,  Prof Allen Cheng
View all 8 related researchers

Brief description MRSA (golden staph) is resistant to the most useful class of antibiotics: beta-lactams. It is more difficult to treat than antibiotic-sensitive strains. Standard treatment for MRSA is vancomycin but it has high failure rates. Although MRSA is resistant to beta-lactams, lab studies show that they enhance vancomycin’s bacterial killing when used together. CAMERA2 is an RCT comparing vancomycin alone to combination therapy (vancomycin plus flucloxacillin) for adults with MRSA blood stream infection

Funding Amount $AUD 1,162,248.54

Funding Scheme Project Grants

Notes Standard Project Grant